Progress Toward the Elusive<i>Pseudomonas aeruginosa</i>Vaccine

Merakou, Christina; Schaefers, Matthew M.; Priebe, Gregory P.

doi:10.1089/sur.2018.233

Cited by 66 publications

(87 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmaceutical industries are working towards the development of vaccines to tackle the antimicrobial resistance and few are under clinical trials which are believed to be effective against the resistance [143,144]. There are several vaccines such as polysaccharide-protein conjugates, LPS-O antigen, OprI and OprF membrane protein, live-attenuated, flagella and DNA vaccines are known to be invented for the control of antimicrobial resistance of P. aeruginosa.…”

Section: Author Detailsmentioning

confidence: 99%

Antimicrobial Resistance in Pseudomonas aeruginosa: A Concise Review

Mohanty¹,

Baliyarsingh²,

Nayak³

2021

Antimicrobial Resistance - A One Health Perspective

View full text Add to dashboard Cite

Pseudomonas aeruginosa is one of the common species responsible for an array of diseases in the respiratory tract, gastrointestinal tract, urinary tract, bones, joints and different systemic infections of normal and immunocompromised patients as well. It exhibits resistance to a wide variety of antimicrobial agents and expresses diverse molecular epidemiology to various established classes of antibiotics including β-lactams, fluoroquinolones, tetracycline and aminoglycosides. Despite the low permeability, hydrophilicity and nonspecific behavior of the outer membrane to small molecular transport, it is inadequate to explain the degree of resistance in P. aeruginosa. The resistance mechanism of P. aeruginosa against various chemical agents is due to the complex chromosomally encoded genes. Different strains of P. aeruginosa having the inherent capacity for biofilm formation, further boosts the resistance under various environmental factors. This chapter explains pathogenicity, mode and types of resistance of P. aeruginosa, its impact on the economy and available remediation/reduction measures and treatments.

show abstract

Section: Author Detailsmentioning

confidence: 99%

Antimicrobial Resistance in Pseudomonas aeruginosa: A Concise Review

Mohanty¹,

Baliyarsingh²,

Nayak³

2021

Antimicrobial Resistance - A One Health Perspective

View full text Add to dashboard Cite

show abstract

“…It also has the capability of forming biofilms on surfaces of medical devices such as catheters, ventilators, in addition to mucosal membranes 3 . Up till now, no licensed vaccine is available against P. aeruginosa infection despite the tremendous efforts made during the last four decades 4 . Different types of vaccines were developed using different cell associated and secreted P. aeruginosa antigens such as the mucoid substance, high molecular mass alginate components, surface exposed antigens (O and H antigens), polysaccharides, polysaccharideprotein conjugates, outer membrane proteins F and I, the type III secretion system component PcrV, pili and live attenuated vaccines [5][6][7] .…”

Section: Introductionmentioning

confidence: 99%

Recombinant Flagellin and Incomplete Freund’s Adjuvant Potentiate the Vaccine Efficacy of the Iron Acquisition Protein (HitA) of Pseudomonas aeruginosa

Elhosary

Guink

Abdel-Bary

et al. 2020

Journal of Advanced Pharmacy Research

View full text Add to dashboard Cite

Objectives: Pseudomonas aeruginosa is a notorious bacterial pathogen that can cause a variety of infections with high morbidity and mortality. The increasing multi-drug resistance of this pathogen makes it urgent to develop an effective vaccine. This study aimed at evaluation of the immunoadjuvant effect of flagellin (FliC) of Salmonella enterica and incomplete Freund's adjuvant (IFA) on the protective vaccine efficacy of P. aeruginosa recombinant iron acquisition protein (HitA). Methods: In this work, recombinant HitA, FliC and fused FliC-F-HitA proteins were expressed in Escherichia coli after cloning their respective genes into pQE31 plasmid vector. The proteins were purified using metal affinity chromatography. The immunoadjuvant effect of FliC was examined upon mixing as well as fusion with HitA antigen of P. aeruginosa in the presence of incomplete Freund's adjuvant (IFA). This was tested by active immunization followed by challenge using P. aeruginosa murine infection model. Results: Two weeks after the last immunization dose, serum samples were tested for antibody response which showed significant HitA-specific IgG antibody response in all immunized groups compared to control groups. A significant reduction in bacterial burden of lungs from mice immunized with HitA/FliC/IFA mixture was observed after challenge. Opsonophagocytic assay and liver histopathological examination confirmed the previous results. Conclusion: Overall, HitA recombinant protein is considered a promising vaccine candidate against P. aeruginosa upon mixing with S. enterica flagellin protein FliC and IFA.

show abstract

“…Our historical experience fighting against pathogenic microorganisms indicates that vaccines are one of the effective weapons to prevent and control them. [13][14][15][16] Hence, the successful development of the P. aeruginosa vaccine will not only reduce the incidence of infectious diseases, lessen the indiscriminately use of antibiotics, but also reduce the severity of antibiotic resistance. In the past 40 years, numerous vaccines have been developed against P. aeruginosa infection, and protective antigens used in these studies included lipopolysaccharide (LPS), polysaccharide, polysaccharide conjugates, extracellular protein, outer membrane protein (OMP), flagella, type 3 secretion system (T3SS), IC 43, 17) as well as pili.…”

Section: Introductionmentioning

confidence: 99%

Construction of Genomic Library and High-Throughput Screening of <i>Pseudomonas aeruginosa</i> Novel Antigens for Potential Vaccines

Wen

et al. 2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Hospital-acquired infections with Pseudomonas aeruginosa have become a great challenge in caring for critically ill and immunocompromised patients. The cause of high mortality is the presence of multi-drug resistant (MDR) strains, which confers a pressing need for vaccines. Although vaccines against P. aeruginosa have been in development for more than several decades, there is no vaccine for patients at present. In this study, we purified genomic DNA of P. aeruginosa from sera of patients affected, constructed genome-wide library with random recombinants, and screened candidate protein antigens by evaluating their protective effects in vivo. After 13-round of screening, 115 reactive recombinants were obtained, among which 13 antigens showed strong immunoreactivity (more than 10% reaction to PcrV, a well-characterized V-antigen of P. aeruginosa). These 13 antigens were: PpiA,

show abstract

Progress Toward the ElusivePseudomonas aeruginosaVaccine

Cited by 66 publications

References 99 publications

Antimicrobial Resistance in Pseudomonas aeruginosa: A Concise Review

Antimicrobial Resistance in Pseudomonas aeruginosa: A Concise Review

Recombinant Flagellin and Incomplete Freund’s Adjuvant Potentiate the Vaccine Efficacy of the Iron Acquisition Protein (HitA) of Pseudomonas aeruginosa

Construction of Genomic Library and High-Throughput Screening of <i>Pseudomonas aeruginosa</i> Novel Antigens for Potential Vaccines

Contact Info

Product

Resources

About